Reaktionsgleichung
[NH2:1][CH:2]([C:5]1[C:6](=[O:16])[NH:7][C:8]([CH:11]2[CH2:15][CH2:14][CH2:13][CH2:12]2)=[N:9][N:10]=1)[CH2:3][CH3:4].[CH:17]1([CH2:23][C:24](O)=[O:25])[CH2:22][CH2:21][CH2:20][CH2:19][CH2:18]1>>[CH:17]1([CH2:23][C:24]([NH:1][CH:2]([C:5]2[C:6](=[O:16])[NH:7][C:8]([CH:11]3[CH2:15][CH2:14][CH2:13][CH2:12]3)=[N:9][N:10]=2)[CH2:3][CH3:4])=[O:25])[CH2:22][CH2:21][CH2:20][CH2:19][CH2:18]1Komponenten
3
Versuchsvorschrift
In analogy to the procedure for Example 58A, 150 mg (0.67 mmol) 6-(1-aminopropyl)-3-cyclopentyl-1,2,4-triazin-5(4H)-one, 96 mg (0.67 mmol) cyclo-hexylacetic acid and proportionate amounts of the other reagents are used. The crude product is used in the next step without further purification.
Aufarbeitung
- customThe crude product is used in the next step without further purification
Quellen und Nachweise
- ORD-Eintrag
- ord-5df41889bf2647ffb1b74693fb65d127
- Quelldatensatz
- uspto-grants-2006_08
- Patentnummer
- US07087605B2
Verknüpfte Notizen
Wird geladen…